Influenza A Clinical Trial
Official title:
Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)
Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is usually mild, but can cause serious illness or death. The purpose of this study is to test the safety and effectiveness of an antibody against the flu (called intravenous hyperimmune immunoglobulin or IVIG) in people who are hospitalized for severe flu.
Influenza is responsible for thousands of hospitalizations and deaths each year in the United
States and worldwide. One possible new treatment for the flu involves the use of IVIG, a
blood product containing antibodies from people who have recovered from the flu or who have
had a flu shot. The purpose of this study is to evaluate whether IVIG can reduce the severity
and duration of flu in people who are hospitalized with the flu.
The study will enroll participants 18 years and older who are hospitalized with the flu. The
study will enroll participants over one or more flu seasons. Regardless of the date of
enrollment, each participant will be in the study for about 28 days.
At study entry (Day 0), participants will be randomly assigned to one of two groups (Arms A
and B). Participants in both groups will receive standard of care (SOC) treatment for the
flu, but those in Arm A will also receive one dose of IVIG and those in Arm B will receive a
placebo for IVIG. Both IVIG and placebo will be given intravenously over at least 2 hours.
On Day 0, before receiving IVIG or placebo, participants will undergo a symptoms assessment,
blood collection, and a nasopharyngeal (NP) swab to collect a sample of secretions from the
nose and throat.
Additional study visits will occur on Days 1, 2, 3, 7, 14, and 28. Depending on the visit,
participants may take part in the same study procedures that took place on Day 0. On Days 2,
14, and 28, visits for participants who are no longer hospitalized may be conducted over the
phone.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03999554 -
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
|
Phase 1 | |
| Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
| Completed |
NCT02487173 -
Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B
|
N/A | |
| Completed |
NCT01701752 -
Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults
|
Phase 1 | |
| Enrolling by invitation |
NCT03207152 -
Biomarkers Predicting Infectivity in an Experimental Human Influenza Model
|
Phase 1 | |
| Terminated |
NCT05567783 -
A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
|
Phase 2 | |
| Not yet recruiting |
NCT00987012 -
The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients
|
N/A | |
| Not yet recruiting |
NCT05928507 -
FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
|
||
| Completed |
NCT03651544 -
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
|
Phase 1 | |
| Completed |
NCT02623322 -
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults
|
Phase 2 | |
| Completed |
NCT03196661 -
Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population
|
Phase 1 | |
| Recruiting |
NCT06160531 -
Influenza Viral Challenge Study of CC-42344 in Healthy Participants
|
Phase 2 | |
| Recruiting |
NCT06191393 -
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
|
N/A | |
| Completed |
NCT06127108 -
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel
|
N/A | |
| Completed |
NCT05163730 -
Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel
|
N/A | |
| Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
| Recruiting |
NCT04896853 -
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
|
Phase 1 | |
| Not yet recruiting |
NCT05787444 -
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
|
||
| Completed |
NCT05354115 -
Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
|
N/A | |
| Completed |
NCT02014870 -
Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers
|
Phase 1 |